Objectif XCellR8 Limited aims to offer the first completely animal-free test for human acute toxicity. The primary focus is cosmetic product safety but the test may also later be applied to other industry sectors including household products, agrochemicals, medical devices and pharmaceuticals. In this context, animal-free means in vitro human cell culture based methods that do not utilise any animal-derived components. There are currently no validated in vitro tests for acute toxicity. Previous attempts to develop such tests used mouse cells and animal-derived components in the culture system and therefore still ultimately required the sacrifice of animals – an approach that is not considered acceptable by ethical cosmetic companies or by the public. The technological feasibility of the project has already been established, through existing tests of XCellR8’s internally developed proprietary methods. This feasibility assessment project is primarily required to address other practical, commercial, regulatory and financial aspects. It will also expand existing market research to assess the appetite of a greater cross-section of industry for such tests. During the project XCellR8 will investigate the alternative routes for test development and adoption by industry as a non-regulatory test to support product development. The ultimate objective is the international validation of the test and regulatory acceptance via incorporation into OECD Guidelines. The proposed project constitutes scientific advancement, using a fully human based method to assess human safety, as well as providing ethical, financial and commercial advantages over the use of animal tests. This offers true SME business model innovation, with an SME creating a pioneering solution that could bring a fundamental change to the manner in which cosmetic companies (and their suppliers) validate the safety of the ingredients used in their products. Champ scientifique agricultural sciencesagriculture, forestry, and fisheriesagricultureagronomyplant protectionmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugssocial scienceseconomics and businessbusiness and managementbusiness modelssocial sciencespolitical sciencesgovernment systems Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Thème(s) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Appel à propositions H2020-SMEInst-2016-2017 Voir d’autres projets de cet appel Sous appel H2020-SMEINST-1-2016-2017 Régime de financement SME-1 - SME instrument phase 1 Coordinateur XCELLR8 LIMITED Contribution nette de l'UE € 50 000,00 Adresse THE INNOVATION CENTRE SCI-TECH DARESBURY KECKWICK WA4 4FS DARESBURY Royaume-Uni Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région North West (England) Merseyside East Merseyside Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 71 429,00